These may be served by the same agent, such as IL-21, or require different agents capable of advancing T-cell activation and anti-tumour effector functions based upon the utilisation of glycolysis before inducing a metabolic switch to promote OXPHOS, FAO and the differentiation into long lived memory T-cells. The gene discussed is IL21; the disease is neoplasm.